Ifosfamide Injection - Uses, Dosage, Precautions, Side Effects, and Pharmacological Aspects

Overview

Ifosfamide injection, a chemotherapy medication, was approved by the FDA (Food and Drug Administration) on December 30, 1988. It is a crucial component in the treatment regimen against cancer. When utilized alongside other approved antineoplastic agents, Ifosfamide injection plays a pivotal role in the third-line chemotherapy treatment of germ-cell testicular cancer. This therapy regimen underscores its significance in combating this specific type of cancer, offering hope and effective treatment options for patients facing this diagnosis.

Drug Group

Ifosfamide Injection belongs to the drug group known as alkylating agents. These chemotherapy drugs work by interfering with cancer cells' DNA or deoxyribonucleic acid, preventing them from growing and dividing. Alkylating agents are used to treat various types of cancer. Ifosfamide Injection is used explicitly in treating germ cell testicular cancer, among other conditions.

Indications

Ifosfamide injection is recommended for use alongside other approved antineoplastic drugs as part of third-line chemotherapy for germ-cell testicular cancer. When administered, it should be coupled with mesna (a medication) to prevent hemorrhagic cystitis (a medical condition characterized by bladder inflammation, leading to bleeding and irritation of the bladder lining).

Dosage Forms and Available Strengths

• The single-dose vial contains 1 gram (g).

• The single-dose vial contains 3 grams.

Warnings and Precautions

• Myelosuppression, Immunosuppression, and Infections: Ifosfamide treatment can lead to myelosuppression (reduction in the production of blood cells) and significant immune suppression, increasing the risk of severe infections, including fatal outcomes. Myelosuppression may manifest as leukopenia (a low white blood cell count), neutropenia (a low neutrophil level), thrombocytopenia (a low platelet count), and anemia (a low red blood cell count). Immunocompromise can result in serious infections such as pneumonia (a lung infection) and sepsis (a severe response to infection affecting the whole body).

• Central Nervous System Toxicity or Neurotoxicity: Administration of Ifosfamide may cause CNS or central nervous system toxicity and other neurotoxic (damaging brain) effects, including drowsiness, confusion, hallucinations (imagination of unreal things), and seizures (sudden, uncontrolled brain activity). Neurologic manifestations may occur within hours to days after treatment and may persist after drug discontinuation.

• Renal and Urothelial Toxicity and Effects: Ifosfamide is nephrotoxic (harmful to kidneys) and urotoxic (harmful to the urinary system), with reported cases of renal parenchymal and tubular necrosis (tissue death in the kidney), acute renal failure (a sudden loss of kidney function), and chronic renal failure (gradual loss of kidney function). Urotoxic effects, particularly hemorrhagic cystitis, are common and can be reduced by prophylactic use of mesna.

• Cardiotoxicity: Reported manifestations of cardiotoxicity (damaging heart) associated with Ifosfamide treatment include arrhythmias (irregular heartbeats), cardiomyopathy (a disease of the heart muscle), pericardial effusion (an accumulation of fluid around the heart), and fibrinous pericarditis (inflammation of the sac around the heart). The risk of cardiotoxic effects is dose-dependent and increases in patients with preexisting cardiac disease.

• Pulmonary Toxicity: Ifosfamide treatment has been associated with interstitial pneumonitis (inflammation of the lung tissue between the air sacs), pulmonary fibrosis (scarring of the lung tissue), and respiratory failure (a state in which the lungs cannot supply sufficient oxygen to the body or remove carbon dioxide effectively). Monitor patients for signs and symptoms indicating pulmonary toxicity (damage or adverse effects on the lungs) and treat as clinically indicated.

• Secondary Malignancies: Treatment with Ifosfamide increases the risk of secondary tumors, including myelodysplastic (abnormal blood cells in the bone marrow) alterations and other malignancies such as lymphoma (cancer that begins in the lymphatic system) and sarcomas (a group of cancers that originate in connective tissues).

• Pregnancy and Fertility: Ifosfamide can cause fetal harm and interfere with fertility in both men and women. Women should not become pregnant, and men should not father a child during therapy with Ifosfamide.

• Anaphylactic or Anaphylactoid Reactions and Impairment of Wound Healing: Ifosfamide has been associated with anaphylactic reactions (severe and potentially life-threatening allergic reactions), which may impair normal wound healing.

• Nursing: Ifosfamide is excreted in breast milk, and breastfeeding should be avoided during treatment.

For Patients

What Is Testicular Cancer?

Testicular cancer is a rare cancer that originates in the testicles, most common in men aged 15 to 35. The two main types are seminomas (slow-growing and radiation-sensitive cancers) and non-seminomas (faster-growing cancers).

Symptoms are:

• A lump or swelling in the testicle.

• Heavy feeling in the scrotum.

• A persistent, dull pain in the lower abdomen or groin.

Risk factors include undescended testicles, family history, and previous testicular cancer. Diagnosis typically involves a physical exam, ultrasound, and blood tests for tumor markers. Treatment options include surgery (removal of the affected testicle), radiation (emission of energy as waves or particles to shrink the cancer growth), chemotherapy (drug therapy to inhibit cancer growth), and surveillance. The prognosis is excellent with early detection, with a five-year survival rate exceeding 95 percent. Regular follow-up is required to monitor for recurrence.

What Are the Clinical Uses of the Ifosfamide Injection?

Ifosfamide injection is used to treat various cancers, including testicular cancer, sarcomas (specifically soft tissue and bone sarcomas), Hodgkin's and non-Hodgkin's lymphomas (cancers of lymphatic tissue), bladder cancer, lung cancer, ovarian cancer, and cervical cancer. It may also be prescribed for other cancers and conditions as determined by a physician. Consult a doctor or pharmacist for detailed information on its use for a specific condition.

What Is the Dosage of the Ifosfamide Injection?

• Ifosfamide injection should be administered intravenously at a 1.2 g/m2 or grams per square meter dose daily for five consecutive days. Treatment cycles are repeated every three weeks or upon recovery from hematologic toxicity (platelets more than or equal to 100,000/µL or per microliter, WBC, or white blood cells more than or equal to 4,000/µL).

• To prevent bladder toxicity, Ifosfamide injection requires ample hydration, comprising a minimum of two liters (68 ounces) of oral or intravenous fluids daily. Additionally, a protective agent like mesna should be employed to diminish the occurrence of hemorrhagic cystitis.

How Are Ifosfamide Injection Administered?

Ifosfamide is supplied as a powder to be reconstituted with liquid and administered intravenously or IV (into a vein) over at least 30 minutes by a healthcare professional in a medical setting. It may be administered once daily for five consecutive days, with treatment cycles repeating every three weeks. This drug is administered as an infusion into a vein by a specially trained healthcare professional in a hospital or clinic. Consult the pediatrician about using this medication in children, as special care may be needed. The doctor may postpone the treatment if the patient encounters specific side effects.

What Are the Side Effects of Ifosfamide Injection?

Ifosfamide may induce side effects like:

• Nausea.

• Vomiting.

• Loss of appetite.

• Diarrhea.

• Mouth and throat ulcers.

• Hair loss.

• General pain and fatigue.

Specific side effects can be severe, like:

• Swelling, red patches, and pain at the injection site.

• Rash.

• Itching.

• Difficulty breathing or swallowing.

• Shortness of breath.

• Wheezing or high-pitched breathing sounds from narrowed airways.

• Irregular heartbeat.

• Chest pain.

• Hoarseness.

• Yellowing of the skin or eyes.

Ifosfamide may elevate the risk of developing other cancers. Discuss this possibility with the doctor before starting the Ifosfamide injection.

What Are the Things to Inform the Doctor Before Taking Ifosfamide Injection?

Before starting Ifosfamide treatment, it is important to:

• Check for Allergies: Inform the doctor and pharmacist about any allergies to Ifosfamide, Cyclophosphamide, other medications, or any components of Ifosfamide injection.

• Medication Review: Share details of all prescription and over-the-counter (OTC) medications, vitamins, and supplements the patient is taking or planning to take. Include medications and drugs such as Aprepitant, certain antifungals (for example, Fluconazole, Itraconazole, Ketoconazole), certain seizure medications (Carbamazepine, Phenobarbital, Phenytoin, etc), allergy or hay fever medications, nausea medications, opioid pain medications, Rifampin, sedatives, sleeping pills, or Sorafenib.

• Herbal Products: Inform the doctor about any herbal products the patient uses, especially St. John's wort.

• Medical History: Notify the doctor if one has received prior treatment with other chemotherapy drugs or radiation therapy. Also, disclose any history of heart, kidney, or liver disease.

• Wound Healing: Be aware that Ifosfamide may slow wound healing.

• Reproductive Health: Ifosfamide may disrupt the normal menstrual cycle in women and inhibit sperm production in men. It may lead to permanent infertility, although it is important not to assume an inability to conceive or impregnate another person. Pregnant or breastfeeding women should inform their doctors before starting Ifosfamide. Avoid becoming pregnant or breastfeeding while receiving Ifosfamide treatment. Use effective birth control during treatment and for six months afterward. If the woman (partner) becomes pregnant during treatment, contact the doctor immediately, as Ifosfamide can harm the fetus.

Dietary Considerations:

Avoid consuming excessive quantities of grapefruit or grapefruit juice while taking this medication.

Missed Dose

It is important to take every dose. If an appointment cannot be made, contact the doctor or healthcare professional.

Overdose

Patients who experience an overdose should be carefully monitored for potential toxic effects. Overdose can lead to severe complications, including CNS toxicity, kidney problems, bone marrow suppression, and mucositis (inflammation of the mucosa). General supportive measures should be taken to manage toxicity, including appropriate treatment for concurrent infections or other issues. Ifosfamide and its metabolites can be removed from the body through dialysis (a procedure for removing waste and excess fluid from the blood). Mesna, a medication used to prevent bladder inflammation, may also be beneficial in managing urotoxic effects caused by overdose.

Storage:

Keep in a controlled room between 20 to 25 degrees Celsius or °C (68 to 77 degrees Fahrenheit or °F). Protect from temperatures at or above 30°C (86°F). Single-dose vials designed for constitution and administration through intravenous infusion, each containing either 1 gram or 3 grams of sterile Ifosfamide.

Handling Precautions:

Exercise caution when handling Ifosfamide injections. The handling and preparation of Ifosfamide should always adhere to current guidelines on the safe handling of cytotoxic agents, as several guidelines on this subject have been published. Skin reactions may occur due to accidental exposure to Ifosfamide injection. Always wear impervious gloves when handling vials and solutions containing Ifosfamide injection to reduce the risk of dermal exposure. If the Ifosfamide injection solution comes into contact with the skin or mucosa, swiftly cleanse the skin with soap and water or flush the affected mucous membrane with plenty of water.

Disposal:

Expired, unused, or unneeded medication should be safely discarded by contacting the local garbage or recycling department or a nearby pharmacist for a take-back program. If a take-back program is unavailable, follow the FDA guidelines for safe drug disposal, which can be found on their website.

For Doctors

Description

Ifosfamide is a chemotherapeutic agent chemically related to nitrogen mustards and a synthetic analog of cyclophosphamide. Its chemical structure is 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide. The molecular formula of Ifosfamide is C7H15Cl2N2O2P, with a molecular weight of 261.1. Ifosfamide is a soluble white crystalline powder in water. The formulation does not contain any excipients. Each vial contains either 1 gram or 3 grams of sterile Ifosfamide.

Pharmacological Actions of Ifosfamide Injection:

Mechanism of Action: Ifosfamide, a prodrug, is activated by hepatic cytochrome P450 enzymes. This activation involves hydroxylation at the ring carbon atom, forming 4-hydroxyifosfamide and its ring-opened aldo tautomer. This process generates the cytotoxic compound acrolein, alkylating isophosphoramide mustard, and non-toxic by-products. Although its exact mechanism is unclear, ifosfamide primarily exerts its cytotoxic effects by forming DNA crosslinks through alkylation at guanine N-7 positions, resulting in cell death.

Pharmacokinetics

Ifosfamide's pharmacokinetics in humans vary based on dosage and time.

At single doses of 3.8 to 5 g/m2, plasma concentrations decline in two phases, with an average elimination half-life of about 15 hours. At doses of 1.6 to 2.4 g/m2/day (grams per meter square per day), plasma decay is monoexponential, with an elimination half-life of around seven hours.

• Distribution: Ifosfamide's distribution volume approximates total body water volume, indicating minimal tissue binding. Little plasma protein binding occurs, but extensive binding by red blood cells occurs. It is not a substrate for P-glycoprotein.

• Metabolism: It is extensively metabolized in humans through two pathways, resulting in active and inactive metabolites.

• Excretion: After administration, 70 to 86 percent of the radioactivity is recovered in urine as metabolites, with 61 percent excreted as the parent compound. Two primary urinary metabolites have been identified.

• Pediatrics: In pediatric patients aged one to 18, population pharmacokinetic analysis showed clearance and volume of distribution estimates with interindividual variability.

• Effect of Age: In patients aged 40 to 71 years, elimination half-life increased with age, possibly due to changes in the volume of distribution. Total plasma clearance and renal clearance did not significantly change with age.

Non-Clinical Toxicity

• Carcinogenicity: Ifosfamide is carcinogenic in rats, causing uterine leiomyosarcomas and mammary fibroadenomas at doses equivalent to a small fraction of the human dose when given by abdominal cavity injection three times a week for 52 weeks.

• Mutagenicity: Ifosfamide shows mutagenic properties in laboratory tests with bacteria and mammalian cells. In live animals, it induces mutations in mouse and fruit fly germ cells, increasing mutations and death, particularly in male mice and fruit flies.

• Impairment of Fertility: Higher oral doses of Ifosfamide induced testicular atrophy and seminiferous tubular epithelium degeneration in beagle dog studies. In rats, high intraperitoneal doses led to reduced sperm production.

Contraindications of Ifosfamide Injection:

The contraindications are:

• Known hypersensitivity to Ifosfamide.

• Urinary outflow obstruction (blockage or restriction in urine flow from the bladder).

Drug Interactions of Ifosfamide Injection:

Inducers of CYP3A4:

• Carbamazepine.

• Phenytoin.

• Fosphenytoin.

• Phenobarbital.

• Rifampin.

• St. John's Wort.

Inhibitors of CYP3A4:

• Ketoconazole.

• Fluconazole.

• Itraconazole.

• Sorafenib.

• Aprepitant.

• Fosaprepitant.

• Grapefruit.

• Grapefruit juice.

Clinical Studies

In a study, 59 patients with refractory testicular cancer received a combination therapy, including Ifosfamide, Cisplatin, and either Etoposide or Vinblastine. The choice between Etoposide and Vinblastine was based on prior treatment outcomes. The combination therapy resulted in a notable enhancement in disease-free status and overall response compared to historical controls. Patients treated with the combination therapy experienced a median survival duration exceeding two years, compared to less than one year in the control group.

Additionally, in another study involving 50 patients with germ cell testicular cancer, treatment with Ifosfamide, Cisplatin, and either Vinblastine or Etoposide showed promising results, with ten patients surviving for two to five years after treatment. Four of these long-term survivors were rendered cancer-free by surgical resection following treatment with the Ifosfamide regimen.

Use in Specific Populations

1. Pregnancy:

• Ifosfamide can harm the fetus if used during pregnancy.

• Animal studies show it may cause birth defects.

• Women should avoid pregnancy during treatment, and men should avoid fathering a child for six months after treatment.

• Breastfeeding is not recommended during treatment.

2. Pediatric Use: Safety and effectiveness not established in children.

3. Geriatric Use:

• Use caution in elderly patients due to possible liver, kidney, or heart issues.

• Elimination of Ifosfamide slows with age, especially in those over 40.

4. Renal Impairment: Monitor closely for toxicity in patients with kidney problems. A dose reduction may be needed.

5. Hepatic Impairment: Use caution in patients with liver problems, as Ifosfamide is processed in the liver.